Epilepsy is a central nervous system disorder involving spontaneous and recurring seizures
that affects 50 million individuals globally. Because approximately one-third of patients with …

The synaptic vesicle glycoprotein SV2A belongs to the major facilitator superfamily (MFS) of
transporters and is an integral constituent of synaptic vesicle membranes. SV2A has been …

Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …

Brivaracetam (BRV), the n-propyl analogue of levetiracetam (LEV), is the latest antiepileptic
drug (AED) to be licensed in Europe and the USA for the adjunctive treatment of focal-onset …

Brivaracetam (BRV) is a high‐affinity synaptic vesicle glycoprotein 2A ligand that is
structurally related to levetiracetam (LEV). Compared to LEV, its affinity to the ligand is> 10 …

Brivaracetam is the latest approved antiepileptic drug in focal epilepsy and exhibits high
affinity as SV2A-ligand. More than two thousand patients have received brivaracetam within …

ABSTRACT Introduction: Antiseizure drugs (ASDs) play a central and crucial role in the
treatment of epilepsy patients, as the majority require anticonvulsant treatment for an …

Objectives The primary objective of the study was to analyze the efficacy of brivaracetam
(BRV) in pediatric patients 12 months after starting treatment. The secondary objective was …

Background: Progressive myoclonus epilepsies (PMEs) are a group of rare inherited
diseases featuring a combination of myoclonus, seizures and variable degree of cognitive …

Currently information is available for 20 potential anti-seizure drugs in clinical development.
They include candidates with mechanisms of action similar to those of marketed AEDs …